Back to Results

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohns Disease V: 05 March 2018

Study category: Digestive Health

Is this Study for You?

Let's Get Started!



Type of Study



Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Mark Gerich,  MD

Mark Gerich, MD

Study ID

Protocol Number: 16-2456

More information available at NCT02914561

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers